Rifampicin in MSA

Status: Complete

Rifampicin in Multiple System Atrophy. The purpose of this study was to determine whether Rifampicin was effective in slowing or reversing the progression of multiple system atrophy (MSA). Research studies indicate that there is an abnormality in protein synthesis and structure in parts of the brain responsible for MSA (protein misfolding) and that the drug Rifampicin could potentially prevent or reverse this protein alteration. The study was performed on participants with early MSA and was part of the Autonomic Disorders Consortium in collaboration with Phillip Low, MD (Mayo Clinic). http://clinicaltrials.gov/ct2/show/NCT01287221

Eligibility: This study was open to people with multiple system atrophy.

IRB#: R10-01813

Sponsor: National Institutes for Health